すべての画像(1)

主要文書

原産地証明書（COO）/試験成績書（COA）

EHU125271

MISSION^® esiRNA

Name: MISSION<SUP>®</SUP> esiRNA
Brand: SIGMA

targeting human PLAUR

ログイン組織・契約価格を表示する

すべての画像(1)

About This Item

UNSPSCコード:

41105324

NACRES:

NA.51

おすすめの製品

Slide 1 of 10

1 of 10

Roche

SITRAN-RO

X-tremeGENE^™ siRNAトランスフェクション試薬

Sigma-Aldrich

EHU132661

MISSION^® esiRNA

Sigma-Aldrich

SIC001

MISSION^® siRNA Universal Negative Control #1

SIRNA

MISSION^® siRNA Product Offerings

Roche

XTG360-RO

X-tremeGENE^™ 360トランスフェクション試薬

Sigma-Aldrich

SHC016

MISSION^® pLKO.1-puro 非標的shRNAコントロールプラスミドDNA

SHRNA

MISSION^® shRNA Product Offerings

Sigma-Aldrich

SHC216

MISSION^® TRC2 pLKO.5-puro非標的shRNAコントロールプラスミドDNA

Roche

XTG9-RO

X-tremeGENE^™ 9 DNAトランスフェクション試薬

Roche

XTGHP-RO

X-tremeGENE^™ HP DNA トランスフェクション試薬

詳細

品質水準

100

製品種目

MISSION^®

フォーム

lyophilized powder

esiRNA cDNA標的配列

GACCCTGAGCTATCGGACTGGCTTGAAGATCACCAGCCTTACCGAGGTTGTGTGTGGGTTAGACTTGTGCAACCAGGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCGTTACCTCGAATGCATTTCCTGTGGCTCATCAGACATGAGCTGTGAGAGGGGCCGGCACCAGAGCCTGCAGTGCCGCAGCCCTGAAGAACAGTGCCTGGATG

Ensembl |ヒトアクセッション番号

ENSG00000011422

NCBIアクセッション番号

NM_001005376

輸送温度

ambient

保管温度

−20°C

遺伝子情報

human ... PLAUR(5329) , PLAUR(5329)

詳細

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

法的情報

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

保管分類コード

10 - Combustible liquids

引火点(°F)

Not applicable

引火点(℃)

Not applicable

最新バージョンのいずれかを選択してください：

試験成績書（COA）

Lot/Batch Number

ZPT

WNS

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

COAを検索

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Urokinase-type plasminogen activator receptor inhibits apoptosis in triple-negative breast cancer through miR-17/20a suppression of death receptors 4 and 5.

Xin Li et al.

Oncotarget, 8(51), 88645-88657 (2017-11-29)

Dissection and understanding of the molecular pathways driving triple-negative breast cancer (TNBC) are urgently needed to develop efficient tailored therapies. Aside from cell invasion and metastasis, the urokinase-type plasminogen activator receptor (uPAR) has been linked to apoptosis resistance in breast

Role of plasminogen activator inhibitor-1 in methotrexate-induced epithelial-mesenchymal transition in alveolar epithelial A549 cells.

Yohei Yamagami et al.

Biochemical and biophysical research communications, 525(3), 543-548 (2020-03-03)

There is increasing evidence that epithelial-mesenchymal transition (EMT) contributes to the development of organ fibrosis. We demonstrated that methotrexate (MTX) clearly induced EMT through the transforming growth factor (TGF)-β-related signaling pathway in human alveolar epithelial cell line, A549. However, critical

Urokinase receptor deficiency results in EGFR-mediated failure to transmit signals for cell survival and neurite formation in mouse neuroblastoma cells.

K D Rysenkova et al.

Cellular signalling, 75, 109741-109741 (2020-08-22)

Urokinase-type plasminogen activator uPA and its receptor (uPAR) are the central players in extracellular matrix proteolysis, which facilitates cancer invasion and metastasis. EGFR is one of the important components of uPAR interactome. uPAR/EGFR interaction controls signaling pathways that regulate cell

Urokinase receptor regulates nerve regeneration through its interaction with α5β1-integrin.

P S Klimovich et al.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 125, 110008-110008 (2020-03-20)

Urokinase receptor (uPAR) promotes extracellular matrix proteolysis, regulates adhesion and cell migration, transduces intracellular signals through interactions with the lateral partners. The expression of uPAR and urokinase (uPA) is significantly upregulated in peripheral nerves after injury, however, little is known

Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo.

Sven Wach et al.

Molecular therapy. Nucleic acids, 16, 272-283 (2019-04-02)

MIR143 is pathologically downregulated and may function as a tumor suppressor in prostate cancer. Likewise, the urokinase plasminogen activator receptor (UPAR) is overexpressed in prostate carcinoma, representing a negative prognostic marker and putative therapeutic target gene. In this paper, we

主要文書

MISSION^® esiRNA